pharmaceutical investing La Jolla Pharmaceutical Company Gets European Commission Approval for GIAPREZA
pharmaceutical investing La Jolla Pharmaceutical Company Receives Orphan Designation from FDA for LJPC-0118
pharmaceutical investing La Jolla Pharmaceutical Company Announces U.S. FDA’s Grant of Breakthrough Therapy Designation for LJPC-0118
pharmaceutical investing La Jolla Pharmaceutical Company Announces European Medicines Agency Validation of Marketing Authorisation Application for GIAPREZA
Alvopetro Announces Q3 2026 Dividend of US$0.12 Per Share and Supplementary Information on December 31, 2025 Prospective Resources
Skyharbour Partner Company Purecore Commences Data Compilation and Target Generation at The Yurchison Uranium Property
